Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging (CVMRI)

This study has been terminated.

(Principal Investigator is deceased)

Sponsor:

Information provided by (Responsible Party):

John M. Brock, University of California, Davis

ClinicalTrials.gov Identifier:

NCT00593541

First received: January 3, 2008

Last updated: November 30, 2015

Last verified: November 2015

History of Changes

Purpose

This Protocol is intended to facilitate development and testing of new cardiovascular MRI software capabilities by UC Davis Research Faculty, as well as to facilitate the evaluation of new software capabilities provided by GE and Siemens.

Condition
Abnormalities, Cardiovascular


Study Type:	Observational
Study Design:	Observational Model: Case Control Time Perspective: Prospective
Official Title:	Development of New Software Capabilities for Use With Cardiovascular Magnetic Resonance Imaging

Resource links provided by NLM:

MedlinePlus related topics: MRI Scans

U.S. FDA Resources

Further study details as provided by University of California, Davis:

Primary Outcome Measures:

Extend or generalize certain capabilities, such as new data acquisition pulse sequences, new image processing and analysis software for structural and functional analysis of the MR images [ Time Frame: Post-scanning ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Improve image quality by various techniques (e.g. reducing the effects of motion) [ Time Frame: Post-scanning ] [ Designated as safety issue: No ]


Enrollment:	42
Study Start Date:	May 1999
Study Completion Date:	July 2014
Primary Completion Date:	July 2014 (Final data collection date for primary outcome measure)

Detailed Description:

This protocol will permit normal subjects, as well as patients with suspected or proven medical conditions, to undergo MRI studies using the new software capabilities. This Protocol is not restricted to imaging of a particular organ system or disease. The Protocol does not involve injection of any contrast agent, or other minimally-invasive or invasive procedure. It is intended only for those cases for which the only requirement of the subject is to relax and lie still while imaging is being performed.

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes
Sampling Method:	Non-Probability Sample

Study Population

Noraml volunteers and patients with known or suspected cardiovascular disease

Criteria

Inclusion Criteria:

18 years of age or older
Ability to give informed, written consent
Not Pregnant or breastfeeding

Exclusion Criteria:

Electrically, magnetically, or mechanically activated implants (for example, cardiac-pacemakers)
Ferromagnetic implant, such as an aneurysm clip, surgical clip, or prosthesis
History of uncontrolled claustrophobia

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00593541

Sponsors and Collaborators

John M. Brock

Investigators


Principal Investigator:	Michael H Buonocore, MD, PhD	University of California, Davis

More Information


Responsible Party:	John M. Brock, Principal Investigator, University of California, Davis
ClinicalTrials.gov Identifier:	NCT00593541 History of Changes
Other Study ID Numbers:	200210689
Study First Received:	January 3, 2008
Last Updated:	November 30, 2015
Health Authority:	United States: Institutional Review Board

Keywords provided by University of California, Davis:


MRI

Additional relevant MeSH terms:


Cardiovascular Abnormalities Cardiovascular Diseases Congenital Abnormalities

ClinicalTrials.gov processed this record on September 28, 2016

To Top